1. Overview
Factor II (Prothrombin) mutation, also known as Prothrombin G20210A mutation, is an inherited genetic condition that increases an individual’s predisposition to abnormal blood clot formation. This mutation occurs due to a G to A substitution at nucleotide position 20210 in the 3′ untranslated region of the F2 gene, leading to elevated levels of prothrombin (clotting factor II). Increased prothrombin levels contribute to a hypercoagulable state, thereby raising the risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
The condition follows an incomplete autosomal dominant inheritance pattern with variable expression. While many individuals carrying the mutation may remain asymptomatic, the overall risk of thrombosis is increased approximately 2–4 fold in heterozygotes and further elevated in homozygous individuals.
2. Symptoms
The presentation highlights that the Factor II mutation itself does not produce direct symptoms. Clinical manifestations arise when thrombotic events occur. These may include unprovoked or recurrent venous thromboembolism, thrombosis occurring at a young age (particularly under 50 years), or clots forming at unusual anatomical sites such as cerebral, hepatic, or mesenteric veins. Symptoms are therefore related to the location and severity of clot formation rather than the mutation alone.
3. Causes
The primary cause of Factor II mutation is a genetic alteration in the F2 gene. The G20210A substitution results in increased production of prothrombin, which enhances blood clotting activity. This genetic change is inherited and may be passed across generations. The mutation increases susceptibility to clotting disorders, particularly in situations that further promote thrombosis, such as surgery, prolonged immobility, pregnancy, or estrogen exposure.
4. Risk Factors
Several risk factors are associated with the clinical significance of Factor II mutation. Individuals with a personal or family history of venous thromboembolism, recurrent VTE episodes, or thrombosis at an early age are at higher risk. The risk is further increased in those who are homozygous for the mutation or who have combined inherited thrombophilic defects, such as co-inheritance with the Factor V Leiden mutation.
Women with the mutation face additional risk during pregnancy, the postpartum period, or while using estrogen-containing oral contraceptives or hormone therapy. The likelihood of recurrence after an initial thrombotic event is also significantly higher in mutation carriers.
5. Prevention and Clinical Management
Although most individuals with the Factor II mutation do not require routine treatment, preventive measures are essential during high-risk situations. Proper counseling of patients and their relatives is emphasized, along with obtaining informed consent prior to genetic testing. Preventive strategies include heightened vigilance during periods of increased thrombotic risk, such as surgery or long travel.
The presentation also outlines indications for genetic testing, including unexplained or recurrent VTE, thrombosis at unusual sites, family history of VTE, and elevated prothrombin levels. Accurate sample collection, handling, and storage are critical for reliable results. Diagnostic methods include PCR-based techniques, RFLP analysis, real-time PCR, DNA sequencing, and allele-specific PCR.
A negative test indicates the absence of the mutation, while a positive result has important implications for long-term risk assessment and clinical decision-making. Limitations of testing are acknowledged, as rare F2 gene variants other than G20210A may not be detected.
